DEVELOP A HEMOCOMPATIBLE, EASY-TO-USE, COST-EFFECTIVE BLOOD PURIFIC

Information

  • Research Project
  • 8740701
  • ApplicationId
    8740701
  • Core Project Number
    N43HB000000
  • Full Project Number
    268201300044C-0-0-1
  • Serial Number
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/5/2013 - 11 years ago
  • Project End Date
    3/4/2014 - 11 years ago
  • Program Officer Name
  • Budget Start Date
    -
  • Budget End Date
    -
  • Fiscal Year
    2013
  • Support Year
  • Suffix
  • Award Notice Date
    -
Organizations

DEVELOP A HEMOCOMPATIBLE, EASY-TO-USE, COST-EFFECTIVE BLOOD PURIFIC

Red blood cell (RBC) products for transfusion undergo metabolic and physical changes during storage characterized as RBC storage lesions that may result in extravascular hemolysis and inflammation, vasoconstriction, and potentially compromised oxygenation upon transfusion. To address this defect, we have proposed the rational design and development of HemoDefend, a hemocompatible, highly porous polymer bead optimized to broadly remove contaminants such as free hemoglobin, potassium, reactive antibodies, bioactive lipids, inflammatory cytokines, reactive proteins and microvesicles from stored pRBCs based on a proven pore capture and surface adsorption technology platform. These hemocompatible beads would be assessed in two configurations: 1) Beads-in-a-Bag, and 2) a dockable, in-line filter. In the first approach, the beads will be placed directly into the blood bag to adsorb blood contaminants during the storage period. In the second approach, the beads would be contained in a small in-line cartridge placed between the blood bag and the patient. After identifying optimal polymer sorbents, we will evaluate each test configuration for the ability to remove 11 contaminants and inflammatory mediators from pRBC units. Given the extended direct contact with erythrocytes, we will specifically evaluate seven parameters to assess hemocompatibility of the bead candidates. We will also evaluate whether HemoDefend treatment can prevent some of the deleterious morphological changes that occur to stored RBCs using image capture and differential cell counting. The outcome will be the demonstration of a powerful and easy-to-use blood purification technology to maintain and potentially improve the quality and safety of stored blood.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    N43
  • Administering IC
    HL
  • Application Type
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    203351
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:203351\
  • Funding Mechanism
    SBIR/STTR Contracts
  • Study Section
  • Study Section Name
  • Organization Name
    CYTOSORBENTS, INC.
  • Organization Department
  • Organization DUNS
    830014077
  • Organization City
    MONMOUTH JUNCTION
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    088521977
  • Organization District
    UNITED STATES